Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection

Chagas disease: protecting from chronic parasitic disease An amalgamation of parasitic proteins may be the first effective vaccine against the as yet untreatable chronic phase of Chagas disease. The infliction, caused by the parasite Trypanosoma cruzi (T. cruzi), is the world’s leading cause of infe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrés Sanchez Alberti, Augusto E. Bivona, Natacha Cerny, Kai Schulze, Sebastian Weißmann, Thomas Ebensen, Celina Morales, Angel M. Padilla, Silvia I. Cazorla, Rick L. Tarleton, Carlos A. Guzmán, Emilio L. Malchiodi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ae1f0273188b48babe69f8e20ee1e766
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ae1f0273188b48babe69f8e20ee1e766
record_format	dspace
spelling	oai:doaj.org-article:ae1f0273188b48babe69f8e20ee1e7662021-12-02T11:50:54ZEngineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection10.1038/s41541-017-0010-z2059-0105https://doaj.org/article/ae1f0273188b48babe69f8e20ee1e7662017-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-017-0010-zhttps://doaj.org/toc/2059-0105Chagas disease: protecting from chronic parasitic disease An amalgamation of parasitic proteins may be the first effective vaccine against the as yet untreatable chronic phase of Chagas disease. The infliction, caused by the parasite Trypanosoma cruzi (T. cruzi), is the world’s leading cause of infectious cardiac inflammation and puts one-sixth of the population of Latin America at risk of infection. International collaborators led by Emilio Malchiodi, of the University of Buenos Aires, Argentina, constructed a vaccine (dubbed ‘Traspain’) comprised of key T. cruzi proteins alongside a novel ‘adjuvant’—designed to promote the efficacy of a vaccine by activating inflammatory responses. The chimera and adjuvant combination elicited a promising immune response and also showed the capacity to prevent tissue damage caused by chronic infection. Multi-part vaccines such as Traspain offer an attractive direction for research into vaccines against chronic parasitic infections.Andrés Sanchez AlbertiAugusto E. BivonaNatacha CernyKai SchulzeSebastian WeißmannThomas EbensenCelina MoralesAngel M. PadillaSilvia I. CazorlaRick L. TarletonCarlos A. GuzmánEmilio L. MalchiodiNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 2, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Andrés Sanchez Alberti Augusto E. Bivona Natacha Cerny Kai Schulze Sebastian Weißmann Thomas Ebensen Celina Morales Angel M. Padilla Silvia I. Cazorla Rick L. Tarleton Carlos A. Guzmán Emilio L. Malchiodi Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
description	Chagas disease: protecting from chronic parasitic disease An amalgamation of parasitic proteins may be the first effective vaccine against the as yet untreatable chronic phase of Chagas disease. The infliction, caused by the parasite Trypanosoma cruzi (T. cruzi), is the world’s leading cause of infectious cardiac inflammation and puts one-sixth of the population of Latin America at risk of infection. International collaborators led by Emilio Malchiodi, of the University of Buenos Aires, Argentina, constructed a vaccine (dubbed ‘Traspain’) comprised of key T. cruzi proteins alongside a novel ‘adjuvant’—designed to promote the efficacy of a vaccine by activating inflammatory responses. The chimera and adjuvant combination elicited a promising immune response and also showed the capacity to prevent tissue damage caused by chronic infection. Multi-part vaccines such as Traspain offer an attractive direction for research into vaccines against chronic parasitic infections.
format	article
author	Andrés Sanchez Alberti Augusto E. Bivona Natacha Cerny Kai Schulze Sebastian Weißmann Thomas Ebensen Celina Morales Angel M. Padilla Silvia I. Cazorla Rick L. Tarleton Carlos A. Guzmán Emilio L. Malchiodi
author_facet	Andrés Sanchez Alberti Augusto E. Bivona Natacha Cerny Kai Schulze Sebastian Weißmann Thomas Ebensen Celina Morales Angel M. Padilla Silvia I. Cazorla Rick L. Tarleton Carlos A. Guzmán Emilio L. Malchiodi
author_sort	Andrés Sanchez Alberti
title	Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
title_short	Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
title_full	Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
title_fullStr	Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
title_full_unstemmed	Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
title_sort	engineered trivalent immunogen adjuvanted with a sting agonist confers protection against trypanosoma cruzi infection
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/ae1f0273188b48babe69f8e20ee1e766
work_keys_str_mv	AT andressanchezalberti engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT augustoebivona engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT natachacerny engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT kaischulze engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT sebastianweißmann engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT thomasebensen engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT celinamorales engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT angelmpadilla engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT silviaicazorla engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT rickltarleton engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT carlosaguzman engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT emiliolmalchiodi engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection
_version_	1718395184869277696

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection

Ejemplares similares